Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin- releasing hormone analog and grouped by pretreatment body mass index level

다국어 초록 (Multilingual Abstract)

Purpose: Reported changes in body mass index (BMI) in central precocious puberty (CPP) during and after gonadotropin-releasing hormone analog (GnRHa) treatment are inconsistent. We, therefore, investigated auxological parameters in GnRHa-treated girls with idiopathic CPP (ICPP) until attainment of near final height (NFH).
Methods: From the medical records of 59 ICPP girls who attained NFH after GnRHa therapy, auxological changes were compared between overweight (BMI≥85th percentile) and normal-weight (BMI<85th percentile) groups. BMIs were changed into standard deviation scores (BMISDSs) for subject chronologic age (BMISDS-CA) and bone age (BMISDS-BA).
Results: The incidence of overweight including obesity was high at the start of therapy (35.6%). The predicted adult height (PAH) at start of therapy was significantly shorter than the midparental height (MPH), whereas PAH at end of therapy approached MPH, and NFH was greater than MPH. Height velocity (HV) in the overweight group was higher during GnRHa therapy than that in the normal-weight group, but those in the two groups were not different after therapy until NFH. Both BMISDS-CA and BMISDS-BA increased significantly during therapy, but both BMISDSs decreased significantly after therapy until NFH. At NFH, neither BMISDS was different from that at baseline. In the normal-weight group, both BMISDSs increased during therapy and were maintained until NFH. In the overweight group, neither BMISDS changed during therapy, but there was a decrease after therapy until NFH.
Conclusion: The different patterns of BMISDS change during and after GnRHa therapy until NFH between the 2 groups were related to the different HV during GnRHa therapy.

참고문헌 (Reference)

1 오경원, "한국 소아청소년의 비만 유병률 추이: 1997년과 2005년 비교" 대한소아과학회 51 (51): 950-955, 2008

2 윤주영, "특발성 진성 성조숙증 여아에서 1년간의 성선자극호르몬 방출호르몬 효능약제 치료 전후 비만도의 관계" 대한소아내분비학회 16 (16): 165-171, 2011

3 De Leonibus C, "Update on statural growth and pubertal development in obese children" 4 : e35-, 2012

4 Wolters B, "Treatment with gonadotropinreleasing hormone analogues: different impact on body weight in normal-weight and overweight children" 78 : 304-311, 2012

5 Poretsky L, "The insulin-related ovarian regulatory system in health and disease" 20 : 535-582, 1999

6 양원준, "The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty" 대한소아내분비학회 22 (22): 49-54, 2017

7 Bayley N, "Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards" 40 : 423-441, 1952

8 Arrigo T, "Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty" 150 : 533-537, 2004

9 Greulich WW, "Radiographic atlas of skeletal development of the hand and wrist" Stanford University Press 1959

10 Kanbur NO, "Prevalence of obesity in adolescents and the impact of sexual maturation stage on body mass index in obese adolescents" 14 : 61-65, 2002

11 Traggiai C, "Outcome after depot gonadotrophinreleasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height" 153 : 463-464, 2005

12 McCartney CR, "Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls" 92 : 430-436, 2007

13 Kamp GA, "Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonisttreated children with precocious puberty" 72 : 301-307, 1991

14 van der Sluis IM, "Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy" 87 : 506-512, 2002

15 Heger S, "Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function" 84 : 4583-4590, 1999

16 Pasquino AM, "Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function" 93 : 190-195, 2008

17 Kaplowitz PB, "Link between body fat and the timing of puberty" 121 (121): S208-S217, 2008

18 Palmert MR, "Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty" 84 : 4480-4488, 1999

19 Chen C, "Investigating the relationship between precocious puberty and obesity: a cross-sectional study in Shanghai, China" 7 : e014004-, 2017

20 Wagner IV, "Effects of obesity on human sexual development" 8 : 246-254, 2012

21 Carel JC, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children" 123 : e752-e762, 2009

22 Corripio R, "Changes in body mass index in girls with idiopathic central precocious puberty under gonadotropin-releasing hormone analogue therapy: The Spanish Registry" 86 : 154-160, 2016

23 Lee HS, "Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty" 54 : 497-503, 2016

24 박진아, "Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty" 대한소아내분비학회 22 (22): 27-35, 2017

25 Paterson WF, "Auxological outcome and time to menarche following longacting goserelin therapy in girls with central precocious or early puberty" 61 : 626-634, 2004